Expression pattern of tumour-Associated antigens in hepatocellular carcinoma: Association with immune infiltration and disease progression

British Journal of Cancer

Volumn 109, Issue 4, 2013, Pages 1031-1039

  Liang, J ^a,b   Ding, T ^a,c   Guo, Z W ^b   Yu, X J ^a   Hu, Y Z ^a,b   Zheng, L ^a,b   Xu, J ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CD20 ANTIGEN; CD57 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; GLYPICAN 3; MIDKINE; NY ESO 1 ANTIGEN; PROTEIN SSX 2; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CANCER GROWTH; CANCER PROGNOSIS; CELL INFILTRATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; OVERALL SURVIVAL; PRIORITY JOURNAL; TUMOR DIFFERENTIATION; TUMOR VOLUME;

ADULT; AGED; ALPHA-FETOPROTEINS; ANTIGENS, NEOPLASM; B-LYMPHOCYTES; CARCINOMA, HEPATOCELLULAR; CELL ADHESION MOLECULES; CELL COUNT; DISEASE PROGRESSION; FEMALE; GLYPICANS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KILLER CELLS, NATURAL; LIVER NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; NERVE GROWTH FACTORS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REPRESSOR PROTEINS; YOUNG ADULT;

EID: 84883174371     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.390     Document Type: Article

References (39)

1. Abastado JP (2012) The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor. Cancer Res 72: 2159-2161.
2. Breous E, Thimme R (2011) Potential of immunotherapy for hepatocellular carcinoma. J Hepatol 54: 830-834.
3. Bricard G, Bouzourene H, Martinet O, Rimoldi D, Halkic N, Gillet M, Chaubert P, Macdonald HR, Romero P, Cerottini JC, Speiser DE (2005) Naturally acquired MAGE-A10-And SSX-2-specific CD8\+ T cell responses in patients with hepatocellular carcinoma. J Immunol 174: 1709-1716.
4. Bruix J, Llovet JM (2009) Major achievements in hepatocellular carcinoma. Lancet 373: 614-616.
5. Chew V, Chen J, Lee D, Loh E, Lee J, Lim KH, Weber A, Slankamenac K, Poon RT, Yang H, Ooi LL, Toh HC, Heikenwalder M, Ng IO, Nardin A, Abastado JP (2012) Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut 61: 427-438.
6. Ding T, Xu J, Wang F, Shi M, Zhang Y, Li SP, Zheng L (2009) High tumorinfiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection. Hum Pathol 40: 381-389.
7. Ding T, Xu J, Zhang Y, Guo RP, Wu WC, Zhang SD, Qian CN, Zheng L (2011) Endothelium-coated tumor clusters are associated with poor prognosis and micrometastasis of hepatocellular carcinoma after resection. Cancer 117: 4878-4889.
8. Disis ML (2010) Immune regulation of cancer. J Clin Oncol 28: 4531-4538.
9. Fan ST, Mau LoC, Poon RT, Yeung C, Leung Liu C, Yuen WK, Ming Lam C, Ng KK, Ching Chan S (2011) Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. Ann Surg 253: 745-758.
10. Fridman WH, Pagès F, Sautès-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12: 298-306.
11. Fu YX (2012) New immune therapy targets tumor-Associated environment: from bone marrow to tumor site. Cell Mol Immunol 9: 1-2.
12. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, Li YW, Tang ZY (2007) Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25: 2586-2593.
13. Gao Q, Shi Y, Wang X, Zhou J, Qiu S, Fan J (2012) Translational medicine in hepatocellular carcinoma. Front Med 6: 122-133.
14. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964.
15. Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140: 883-899.
16. He J, Tang XF, Chen QY, Mai HQ, Huang ZF, Li J, Zeng YX (2012) Ex vivo expansion of tumor-infiltrating lymphocytes from nasopharyngeal carcinoma patients for adoptive immunotherapy. Chin J Cancer 31: 287-294.
17. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
18. Jia HL, Ye QH, Qin LX, Budhu A, Forgues M, Chen Y, Liu YK, Sun HC, Wang L, Lu HZ, Shen F, Tang ZY, Wang XW (2007) Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin Cancer Res 13: 1133-1139.
19. Korangy F, Ormandy LA, Bleck JS, Klempnauer J, Wilkens L, Manns MP, Greten TF (2004) Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Res 10: 4332-4341.
20. Kuang DM, Zhao Q, Wu Y, Peng C, Wang J, Xu Z, Yin XY, Zheng L (2011) Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol 54: 948-955.
21. Kerzerho J, Adotevi O, Castelli FA, Dosset M, Bernardeau K, Szely N, Lang F, Tartour E, Maillere B (2010) The angiogenic growth factor and biomarker midkine is a tumor-shared antigen. J Immunol 185: 418-423.
22. Qin LX (2012) Inflammatory immune responses in tumor microenvironment and metastasis of hepatocellular carcinoma. Cancer Microenviron 5: 203-209.
23. Mellman I, Coukos G, Dranoff G (2011) Cancer immunotherapy comes of age. Nature 480: 480-489.
24. Mizukoshi E, Nakamoto Y, Arai K, Yamashita T, Sakai A, Sakai Y, Kagaya T, Yamashita T, Honda M, Kaneko S (2011) Comparative analysis of various tumor-Associated antigen-specific T-cell responses in patients with hepatocellular carcinoma. Hepatology 53: 1206-1216.
25. Nielsen JS, Sahota RA, Milne K, Kost SE, Nesslinger NJ, Watson PH, Nelson BH (2012) CD20\+ tumor-infiltrating lymphocytes have an atypical CD27-memory phenotype and together with CD8\+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res 18: 3281-3292.
26. Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y, Mizuno S, Ishii H, Nakachi K, Konishi M, Nakagohri T, Takahashi S, Gotohda N, Takayama T, Yamao K, Uesaka K, Furuse J, Kinoshita T, Nakatsura T (2012) Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin Cancer Res 18: 3686-3696.
27. Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331: 1565-1570.
28. Thimme R, Neagu M, Boettler T, Neumann-Haefelin C, Kersting N, Geissler M, Makowiec F, Obermaier R, Hopt UT, Blum HE, Spangenberg HC (2008) Comprehensive analysis of the alpha-fetoprotein-specific CD8\+ T cell responses in patients with hepatocellular carcinoma. Hepatology 48: 1821-1833.
29. Topalian SL, Weiner GJ, Pardoll DM (2011) Cancer immunotherapy comes of age. J Clin Oncol 29: 4828-4836.
30. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ (2011) Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29: 235-271.
31. Villanueva A, Hernandez-Gea V, Llovet JM (2012) Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol 10: 34-42.
32. Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C, Savic R, Cornella H, Llovet JM (2010) New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res 16: 4688-4694.
33. Wang XY, Chen HS, Luo S, Zhang HH, Fei R, Cai J (2009) Comparison for detecting NY-ESO-1 mRNA expression levels in hepatocellular carcinoma tissues. Oncol Rep 21: 713-719.
34. Wu Y, Kuang DM, Pan WD, Wan YL, Lao XM, Wang D, Li XF, Zheng L (2013) Monocyte/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions. Hepatology 57: 1107-1116.
35. Xu H, Gu N, Liu ZB, Zheng M, Xiong F, Wang SY, Li N, Lu J (2012a) NY-ESO-1 expression in hepatocellular carcinoma: A potential new marker for early recurrence after surgery. Oncol Lett 3: 39-44.
36. Xu J, Ding T, He Q, Yu XJ, Wu WC, Jia WH, Yun JP, Zhang Y, Shi M, Shao CK, Pan WD, Yin XY, Min J, Zhuang SM, Zheng L (2012b) An in situ molecular signature to predict early recurrence in hepatitis B virus-related hepatocellular carcinoma. J Hepatol 57: 313-321.
37. Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, Budhu A, Zanetti KA, Chen Y, Qin LX, Tang ZY, Wang XW (2008) EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 68: 1451-1461.
38. Yang JD, Roberts LR (2010) Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol 7: 448-458.
39. Zhou J, Ding T, Pan W, Zhu LY, Li L, Zheng L (2009) Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int J Cancer 125: 1640-1648.